People · Operator
Named in public records as an officer, director or promoter · active 2022–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| VerImmune, Inc. | — | Biotechnology | Series A | $5.9M | $21.9M | 2022 |
KEVIN KOH RONGSHENG at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside KEVIN KOH RONGSHENG on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| JOSHUA WEIYUAN WANG | 1 | 2 |
| HAOLIN SUNG | 1 | 1 |
| CHE KOH HSU | 1 | 1 |
| MARTA KOH NEW | 1 | 1 |
| CYNTHIA KOH POH | 1 | 1 |
| ROGER KOH POMERANTZ | 1 | 1 |
| JOHN WEIYUAN TROYER | 1 | 1 |
| CYNTHIA WEIYUAN POH | 1 | 1 |
| JOSHUA WANG | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.